Moreover, compared with untreated control, ZCVCT26@D‐Gel dramatically increased the frequency of CD11c+CD11b+Ly6c+ DCs in the TDLNs, a crucial subset of antigen‐presenting cells (APCs) that played significant roles in the presentation of tumor antigens.[21] These APCs also up‐regulated the level co‐stimulatory marker CD86 (Figure S12, Supporting Information). The gene discussed is CD86; the disease is neoplasm.